#AIDS2016 Intensified TB case-finding among PLHIV: diagnostic yield of Xpert MTB/RIF, Determine TB-LAM and liquid culture Fred Semitala,

Slides:

Advertisements

Similar presentations

Integration of TB and HIV Services: Experiences from the Kericho District Hospital Charles S. Kiptemas, MBChB, MPH Director South Rift Valley HIV Care.

Advertisements

June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.

Improving direct microscopy by overnight bleach sedimentation: a simple tool for peripheral Health Centres Maryline Bonnet 1, Laramie Gagnidze 1, Willie.

Cost-effectiveness of ART and the Three I’s for HIV/TB to prevent tuberculosis among people living with HIV Somya Gupta, Taiwo Abimbola, Anand Date, Amitabh.

Living with HIV, Dying of TB Intensified TB case finding among people living with HIV Adapted from presentation by Colleen Daniels TB/HIV Advocacy Stop.

Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.

Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG.

Jason R. Andrews, MD Stephen D. Lawn, MD, DTM&H Corina Rusu, BA, BS Robin Wood, FCP, MMed, DTM&H Farzad Noubary, PhD Melissa A. Bender, MD, MPH Robert.

Late-outcomes of TB-IRIS William Worodria, MBChB, MMed, PhD Senior EDCTP Fellow Infectious Disease Institute, Kampala, Uganda Mulago Hospital & Complex,

Advocacy for TB POC Diagnostic Javid Syed TB/HIV 15th Core Group Meeting Nov 3-4, Geneva.

Annabel Baddeley Global TB Programme WHO, Geneva

Integrating TB into PWID Services in Indonesia The Works in Progress Dr Siti Nadia, NAP Manager; Dr Dyah Erti Mustikawati, NTP Manager Melbourne AIDS Conference.

Unit 5: IPT Isoniazid TB Preventive Therapy

Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,

Cost-Effectiveness of a Lateral-Flow Urine Lipoarabinomannan Test for TB diagnosis in HIV-infected South African Adults Di Sun1; Susan Dorman2,3,4; Maunank.

Tuberculosis Research of INA-RESPOND on Drug-resistant

COST-BENEFIT OF INTEGRATING CRYPTOCOCCAL ANTIGEN SCREENING AND PREEMPTIVE TREATMENT INTO ROUTINE HIV CARE Radha Rajasingham, David Meya, Melissa Rolfes,

Welcome to I-TECH Nurse Clinical Seminar Series 19 August WHO Recommendations for TB Screening and IPT among People Living with HIV Stacie C.

Management and Development for Health (MDH)

New molecular diagnostic tests for TB: Do patients benefit? HSRC Roundtable 02 June 2014 Pren Naidoo Rory Dunbar, Elizabeth Du Toit, Margaret van Niekerk,

Revision of new diagnostics for TB

Press Briefing: Office of the Vice Chancellor MUK 6 th September 2010 The Infectious Diseases Institute Care and Research Initiatives Dr Alex G Coutinho.

Haileyesus Getahun Stop TB Department WHO Re-conceptualizing ICF and IPT: global progress to date 14 th Core Group Meeting of the TB/HIV Working Group,

Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-

Screening for TB among risk groups in Cambodia Dr. Mao Tan Eang, NTP Director National Center for TB and Leprosy Control, Cambodia TAG Meeting, 9-12 December.

Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.

Integration of TB and HIV Screening, Care and Treatment in Mulago Hospital, Uganda Rhoda Wanyenze, Doris Mwesigire, Henry Luzze, Violet Gwokyalya, Julius.

Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.

GLOBAL TB PROGRAMME Systematic screening for active TB – operational manual and tool to help prioritization Wolfheze 2015 Knut Lönnroth, Global TB Programme.

Integrated Community HIV Testing Campaigns: Leveraging HIV infrastructure for non- communicable diseases July 23, 2012 Gabriel Chamie, Dalsone Kwarisiima,

Challenges of ICF among PLHIV and how to move forward G J Churchyard 17 th April th Core Group Meeting of the TB/HIV Working Group New York.

Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.

Attrition between TB / HIV testing and linkage to care in South Africa’s correctional facilities. 01 December 2015 Vincent Zishiri, Salome Charalambous,

Roundtable. Detection and treatment of TB Andrew Black.

1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.

Community-Based Voluntary Counseling and Testing in Rural South Africa Shenoi SV, Moll AP, Madi J, Guddera V, Madondo T, Turner D, Brooks RP, Kyriakides.

Who is the severely ill HIV+ patient in 2017? Defining advanced HIV

Factors associated with loss to follow up in a primary healthcare clinic practicing test and treat Authors: Julius Kiwanuka1,2, Noah Kiwanuka3, Flavia.

New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.

Incidence of tuberculosis in the first year of antiretroviral treatment in West-African HIV-infected adults B. Tchakounte Youngui1, P. Coffie2, E. Messou3,

Addressing the challenges and successes of expediting TB treatment among PLHIV who are seriously ill: experience from Kenya Masini E & Olwande C National.

Participants 18year old+

LAM assay: overview and practical guidance on its adoption and use

Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort

This is an archived document.

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV- associated pulmonary tuberculosis before antiretroviral therapy:

HIV surveillance in Northern Ireland 2015

Comparing shorter with conventional MDR-TB treatment in Uzbekistan 2-month culture conversion rates and treatment outcomes P du Cros1, A Khamraev2, D Lister3,

Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.

HIV-associated TB mortality and blocks in the cascade

PRIORITIZING TB in 2018 PEPFAR COPS

Table 1: New HIV diagnoses, by UK country,

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV- associated pulmonary tuberculosis before antiretroviral therapy:

World Health Organization

Evidence for use of urinary LAM

Advanced HIV: a WHO perspective

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.

Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,

Screening and diagnosing TB in PLHIV: Challenges and ways forward

24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.

Management and Development for Health (MDH)

Characteristics LAM Result Total (%) 95% CI Odds ratio

The Population Level Impact of Novel, Point-of-Care Screening-Diagnostic Algorithms for Tuberculosis when Administered with Annual HIV Testing in South.

TB Screening and Differentiated Service Delivery: State of the Art

DSD and TB/HIV services in Zimbabwe

Mapping of LF-LAM Uptake with Global Fund & PEPFAR Funding

Emilio Valverde, The Aurum Institute

Public Health Implications

Presentation transcript:

#AIDS2016 Intensified TB case-finding among PLHIV: diagnostic yield of Xpert MTB/RIF, Determine TB-LAM and liquid culture Fred Semitala, MBChB, M.Med, MPH Makerere University, College of Health Sciences

#AIDS2016 HIV & TB TB - leading cause of HIV deaths (1 in 3) worldwide Intensified case finding (ICF) is recommended to reduce TB burden among PLHIV WHO. Global TB Report, 2015 WHO. 3I’s Guidelines, 2011

#AIDS2016 Screen for TB: WHO symptom screen Cough, fever, night sweats, weight loss Test for TB: Xpert MTB/RIF 1 st line confirmatory test for PLHIV ICF algorithm for PLHIV Active TB: Initiate TB treatment Screen-positive Xpert-positive Lawn, et al. Plos MED, 2011 Abed Al-Darraji, et al. PLoS ONE, 2013 LaCourse, et al. JAIDS, 2016 Sensitivity 43-58%

#AIDS2016 Options for novel ICF algorithm Increased speed: Determine TB-LAM LAM, an MTb cell wall antigen Recommended as an “add-on test” for patients with advanced HIV and/or severe illness Increased sensitivity: Culture Gold standard for pulmonary TB diagnosis Unprocessed urine $ per strip Results in 25 min WHO. Urine LAM, =

#AIDS2016 Study Objectives and Design Objectives In the context of ICF, to compare the current TB testing strategy (Xpert MTB/RIF) to TB testing strategies inclusive of urine LAM and/or a single liquid culture Diagnostic accuracy Time-to-diagnosis Design Prospective study among consecutive HIV-infected adults who screened positive for TB by symptoms

#AIDS2016 Design overview Participants: Adults with CD4 count ≤350 cells/μL initiating ART who screened positive for TB by symptoms Setting: Mulago HIV/AIDS Clinic (Kampala, Uganda) (7/2013 – 5/2016) Procedures: Sputum x 1 for Xpert and x 2 for MGIT culture Urine x 1 for Determine TB-LAM (if CD4 count ≤ 200 cells/μL; Grade 2 cut-point) TB testing algorithms: Individual tests (Xpert, LAM, MGIT-1) Test combinations Active TB definition: ≥1 positive sputum MGIT culture

#AIDS2016 Patient flow diagram Patients screened for TB N=963 Screen positive N= 843 (87%) Screen negative, N=120 No TB N=731 (88%) TB N=112 (13%)

#AIDS2016 Demographics and clinical characteristics Characteristic, N (%)Total (N=843) Age (years) † 33 (27-40) Female 264 (55%) CD4 count (cells/µL) † 223 (97-295) CD4 count ≤ 200 cells/µL 563 (58%) Culture-positive TB* 112 (13%) Legend: † Median (IQR); *At least 1 of 2 MGIT cultures.

#AIDS2016 Diagnostic accuracy of individual tests Test Sensitivity, n/N (%) Specificity, n/N (%) Urine LAM (CD4 count ≤200 cells/µL) † 18/85 (21%)274/276 (99%) Xpert MTB/RIF69/112 (62%)727/731 (99%) MGIT-1*88/112 (79%)731/731 (100%) Legend: † If CD4 count ≤200 cells/uL; * MGIT-1 – culture result from the 1 st sputum specimen.

#AIDS2016 Diagnostic accuracy of test combinations Test Combination Sensitivity n/N (%) Specificity n/N (%) Xpert + LAM73/112 (65%)723/731 (99%) LAM + MGIT-192/112 (82%)727/731 (99%) Xpert + MGIT-198/112 (88%)727/731 (99%) Xpert + LAM + MGIT-199/112 (88%)723/731 (99%)

#AIDS2016 Case detection yield and days-to- diagnosis TB testing strategy % TB cases detected (N=112) Median days to TB diagnosis (IQR) LAM21%0 (0-0) Xpert62%0 (0-0) Xpert + LAM65%0 (0-0) MGIT-179%12 (9-16) LAM + MGIT-182%10 (6-15) Xpert + MGIT-188%0 (0-9) Xpert + LAM + MGIT-188%0 (0-8)

#AIDS2016 Conclusions TB prevalence is high among PLHIV initiating ART who screen positive by symptoms The current TB testing strategy for ICF – Xpert alone – misses nearly 40% of all culture-positive TB cases Addition of urine LAM did not significantly increase diagnostic yield beyond that of Xpert alone In the context of ICF, any TB testing strategy not including MGIT misses at least 1/3 of all TB cases More sensitive rapid tests are needed and are likely to have the highest impact in context of ICF

#AIDS2016 Acknowledgments UCSF Adithya Cattamanchi Christina Yoon Makerere University Moses R. Kamya Elly Atuhumuza Alfred Andama Lucy Asege Sandra Mwebe Jane Katende Martha Nakaye Johns Hopkins University David Dowdy Derek Armstrong Funding sources: NIAID K23 UCSF-GIVI CFAR NIAID/PEPFAR UCSF Nina Ireland Program in Lung Health NIH-FIC

#AIDS2016

Performance of TB testing strategies (relative to Xpert MTB/RIF alone) TB testing strategy Difference in sensitivity, % (95% CI) Difference in specificity, % (95% CI) LAM-40% (-53 to -28)-1% (-2 to 1) MGIT-1+17% (5 to 29)1% (0 to 1) Xpert + LAM+4% (-9 to 16)-1% (-1 to 0) LAM + MGIT-1+21% (9 to 32)0% (-1 to -1) Xpert + MGIT-1+26% (15 to 37)0% (-1 to -1) Xpert + LAM + MGIT-1+27% (16 to 38)-1% (-1 to 0)